

S 3738

Hatch-Waxman Integrity Act of 2018

Congress: 115 (2017–2019, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Dec 11, 2018

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Dec 11, 2018)

Official Text: <https://www.congress.gov/bill/115th-congress/senate-bill/3738>

Sponsor

Name: Sen. Hatch, Orrin G. [R-UT]

Party: Republican • **State:** UT • **Chamber:** Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Tillis, Thomas [R-NC]	R · NC		Dec 11, 2018

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Dec 11, 2018

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
115 HR 7251	Identical bill	Dec 11, 2018: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Summary (as of Dec 11, 2018)

Hatch-Waxman Integrity Act of 2018

This bill amends the Federal Food, Drug, and Cosmetic Act and the Securities Exchange Act of 1934 to prevent a generic drug or biosimilar manufacturer from using a specific review process for challenging pharmaceutical drug or biologic patents.

Actions Timeline

- **Dec 11, 2018:** Introduced in Senate
- **Dec 11, 2018:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.